Pfizer announces second-generation EGFR-tyrosine kinase inhibitor target drug Dacutinib (Dozerun ®) officially launched in China
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
lung cancer ranks first in the morbidity and mortality of all types of cancer in ChinaOf these, NSCLC accounts for about 85% of all lung cancer casesIn China, EGFR is the most common type of mutation, with advanced EGFR mutation accounting for about 50%recently, Pfizer announced that the second generation of EGFR-tyrosine kinase inhibitors (TKI) targeteddrug(http://Dacostini (commodity name: Dozerun ®) officially landed in China, while launching the "EAR Lung Cancer Precision Institute" to bring new precision treatment programs for lung cancer patientsOn May 15 this year, Dacostinib was approved by the NationalMedicines(http://Regulatory Authority (NMPA) of China, and can be used as a single drug for first-line treatment of patients with late-stage or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 19 epidermal osteocrinatic deficiency mutation son or 21 exon L858R displacement mutationSeptember 2018, the U.SFood and Drug Administration (
FDA(http://) granted the first-line treatment of Dacosti to patients with advanced or metastatic EGFR mutations in NSCLC, Dakota nini has been approved for first-line treatment for advanced lung cancer in the United States, the European Union, Japan, Canada, etc., and has been granted applications almost simultaneously with the world in China and approved by regulators
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
